Correlation Engine 2.0
Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

Cutaneous Leishmaniasis is a serious public health problem, typically affecting poor populations with limited access to health care. Control is largely dependent on chemotherapies that are inefficient, costly and challenging to deliver. Vaccination is an attractive and feasible alternative because long-term protection is typical in patients who recover from the disease. No human vaccine is yet approved for use, but several candidates are at various stages of testing. Live attenuated parasites, which stimulate long-term immune protection, have potential as effective vaccines, and their challenges relating to safety, formulation and delivery can be overcome. Here we review current data on the potential of live attenuated Leishmania vaccines and discuss possible routes to regulatory approval. Copyright © 2020 Elsevier Inc. All rights reserved.

Citation

A Zabala-Peñafiel, D Todd, H Daneshvar, R Burchmore. The potential of live attenuated vaccines against Cutaneous Leishmaniasis. Experimental parasitology. 2020 Mar;210:107849

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 32027892

View Full Text